Male breast cancer: A review;Cancer du sein chez l'homme: Revue de la littérature

Bulletin du Cancer

Volumn 96, Issue 2, 2009, Pages 181-189

  Comet, B ^a   Cutuli, B ^b   Penault Llorca, F ^c   Bonneterre, J ^a   Belkacemi Y ^d  

^a UNIV LILLE   (France)

^b Polyclinique de Courlancy   (France)

^c CLCC Jean Perrin   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Breast cancer; Chemotherapy; Hormonotheray; Male cancer; Radiotherapy; Trastuzumab

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; CYTOCHROME P450C17; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FLUOROURACIL; HORMONE RECEPTOR; LETROZOLE; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; AGE DISTRIBUTION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; COWDEN SYNDROME; DISEASE ASSOCIATION; EARLY CANCER; FAMILY HISTORY; GENE OVEREXPRESSION; GOLD STANDARD; GYNECOMASTIA; HEREDITY; HIGH RISK PATIENT; HISTOLOGY; HUMAN; KLINEFELTER SYNDROME; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MALE BREAST; MASTECTOMY; OBESITY; OCCUPATIONAL EXPOSURE; ONCOGENE NEU; ORGAN SIZE; OVERALL SURVIVAL; PROGNOSIS; RADIATION EXPOSURE; REVIEW; SENTINEL LYMPH NODE;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODE EXCISION; MALE; MASTECTOMY, MODIFIED RADICAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; TAMOXIFEN; WORLD HEALTH;

EID: 66349132771     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0813     Document Type: Review

References (71)

1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004 ; 101(1) : 51-57 (Pubitemid 38812422)
2. Donegan WL, Redlich PN. Breast cancer in men. Surg Clin North Am 1996 ; 76(2) : 343-363 (Pubitemid 26119153)
3. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006 ; 367(9510) : 595-604. (Pubitemid 43247575)
4. Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, et al. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol 2004 ; 24(3) : 663-670
5. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993 ; 53(4) : 538-549 (Pubitemid 23069261)
6. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 ; 55(1) : 10-30.
7. Muir CS, Maclennan R, Waterhouse JA, Magnus K. Feasibility of monitoring populations to detect environmental carcinogens. IARC Sci Publ 1976 ; 13 : 279-293 (Pubitemid 8044199)
8. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999 ; 126(4) : 775-780 (discussion 80-1). (Pubitemid 29473182)
9. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol 2001 ; 40(4) : 467-471 (Pubitemid 32682030)
10. Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev 2002 ; 11(3) : 253-263
11. Hill A, Yagmur Y, Tran KN, Bolton JS, Robson M, Borgen PI. Localized male breast carcinoma and family history. An analysis of 142 patients. Cancer 1999 ; 86(5) : 821-825
12. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002 ; 4(1) : R2. (Pubitemid 34097557)
13. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997 ; 60(2) : 313-319 (Pubitemid 27058403)
14. Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003 ; 63(2) : 342-347 (Pubitemid 36152491)
15. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002 ; 20(6) : 1480-1490 (Pubitemid 34260526)
16. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997 ; 60(5) : 1079-1084 (Pubitemid 27194092)
17. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 2003 ; 9(12) : 4452-4459 (Pubitemid 37248403)
18. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet 2002 ; 31(1) : 55-59
19. Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP. CHEK2*1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004 ; 108(3) : 475-476 (Pubitemid 37553160)
20. Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004 ; 108(3) : 479-480 (Pubitemid 37549616)
21. Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, et al. A germ-line mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992 ; 2(2) : 132-134
22. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993 ; 2(11) : 1799-1802 (Pubitemid 23326602)
23. Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998 ; 58(7) : 1367-1371 (Pubitemid 28193591)
24. Syrjakoski K, Hyytinen ER, Kuukasjarvi T, Auvinen A, Kallioniemi OP, Kainu T, et al. Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res Treat 2003 ; 77(2) : 167-170 (Pubitemid 36197617)
25. Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB, et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 1999 ; 81(1) : 141-143 (Pubitemid 29415504)
26. Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE. CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 2003 ; 88(6) : 933-936 (Pubitemid 36520882)
27. Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, et al. Male breast cancer in Cowden syndrome patients with germ-line PTEN mutations. J Med Genet 2001 ; 38(3) : 159-164 (Pubitemid 32250866)
28. Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. APMIS 1973 ; 81(3) : 352-358
29. Hultborn R, Hanson C, Kopf I, Verbiene I, Warnhammar E, Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997 ; 17(6D) : 4293-4297 (Pubitemid 28081702)
30. Cocco P, Figgs L, Dosemeci M, Hayes R, Linet MS, Hsing AW. Case-control study of occupational exposures and male breast cancer. Occup Environ Med 1998 ; 55(9) : 599-604. (Pubitemid 28383480)
31. Thomas DB. Breast cancer in men. Epidemiol Rev 1993 ; 15(1) : 220-231 (Pubitemid 23269085)
32. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol 1998 ; 93(2) : 231-233 (Pubitemid 29063974)
33. Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. Am J Surg Pathol 2000 ; 24(1) : 74-80. (Pubitemid 30033399)
34. Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995 ; 31A(12) : 1960-1964 (Pubitemid 26023085)
35. Lartigau E, el-Jabbour JN, Dubray B, Dische S. Male breast carcinoma: a single centre report of clinical parameters. Clin Oncol (R Coll Radiol) 1994 ; 6(3) : 162-166
36. Ben Dhiab T, Bouzid T, Gamoudi A, Ben Hassouna J, Khomsi F, Boussen H, et al. Male breast cancer: about 123 cases collected at the Institute Salah-Azaiz of Tunis from 1979 to 1999. Bull Cancer 2005 ; 92(3) : 281-285
37. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multi-institutional survey. Cancer 1998 ; 83(3) : 498-509. (Pubitemid 28354506)
38. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40-years: 1955-1996. Cancer 1999 ; 85(3) : 629-639
39. Iredale R, Brain K, Williams B, France E, Gray J. The experiences of men with breast cancer in the United Kingdom. Eur J Cancer 2006 ; 42(3) : 334-341 (Pubitemid 43132888)
40. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg 1992 ; 215(5) : 451-457 (discussion 7-9).
41. Evans GF, Anthony T, Turnage RH, Schumpert TD, Levy KR, Amirkhan RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg 2001 ; 181(2) : 96-100. (Pubitemid 32406299)
42. Chen L, Chantra PK, Larsen LH, Barton P, Rohitopakarn M, Zhu EQ, et al. Imaging characteristics of malignant lesions of the male breast. Radiographics 2006 ; 26(4) : 993-1006.
43. Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, et al. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997 ; 33(1) : 35-38 (Pubitemid 27099564)
44. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma-a preliminary report. Cancer 1998 ; 83(10) : 2139-2149 (Pubitemid 28525395)
45. Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, et al. Male breast cancer: Austrian experience. World J Surg 1995 ; 19(5) : 687-692 (discussion 92-3).
46. Cutuli B, Velten M, Dilhuydy JM. Male breast cancer: result of the treatement and pronostic factors in 690 cases. Int J Rad Oncol Biol Phys 1998 ; 42(Suppl. 1).
47. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 2003 ; 127(1) : 36-41.
48. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, et al. Molecular markers in male breast carcinoma. Cancer 1998 ; 83(9) : 1947-1955 (Pubitemid 28503726)
49. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, HER2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002 ; 15(8) : 853-861
50. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000 ; 18(16) : 2948-2956 (Pubitemid 30644118)
51. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER2 in male and female breast carcinoma. Am J Surg 2001 ; 182(4) : 389-392 (Pubitemid 33079093)
52. Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, et al. HER2-neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004 ; 84(3) : 215-223 (Pubitemid 38445371)
53. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002 ; 137(8) : 678-687 (Pubitemid 35176102)
54. Cutuli B, Cohen-Solal-Le-Nir C, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer (MBC): prognostic factors and therapeutic strategies evolution. A French Multicenter retrospective analysis. Proceeding of San Antonio Breast Cancer Symposium, SA, Dec 2007.
55. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993 ; 2(6) : 325-333
56. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007 ; 103(1) : 11-21. (Pubitemid 46653271)
57. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003 ; 349(6) : 546-553 (Pubitemid 36951366)
58. Cimmino VM, Degnim AC, Sabel MS, Diehl KM, Newman LA, Chang AE. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 2004 ; 86(2) : 74-77 (Pubitemid 38580517)
59. Goyal A, Horgan K, Kissin M, Yiangou C, Sibbering M, Lansdown M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004 ; 30(5) : 480-483 (Pubitemid 38701867)
60. De Cicco C, Baio SM, Veronesi P, Trifiro G, Ciprian A, Vento A, et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004 ; 25(2) : 139-143 (Pubitemid 38315416)
61. Hill AD, Borgen PI, Cody 3rd HS. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 1999 ; 25(4) : 442-443 (Pubitemid 29364237)
62. Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006 ; 203(4) : 475-480 (Pubitemid 44416251)
63. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005 ; 10(7) : 471-479 (Pubitemid 41266328)
64. Nahleh ZA. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 2006 ; 32(2) : 101-105 (Pubitemid 43362231)
65. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002 ; 25(3) : 235-237 (Pubitemid 34602542)
66. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006 ; 24(21) : e42-3.
67. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005 ; 90(1) : 26-30. (Pubitemid 40446471)
68. Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 2004 ; 25(4) : 323-324 (Pubitemid 38438416)
69. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987 ; 10(1) : 55-60. (Pubitemid 17007908)
70. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005 ; 104(11) : 2359-2364 (Pubitemid 41691556)
71. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007 ; 8(2) : 193-202. (Pubitemid 46206621)